AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
It is intended for contrast enhancement in MRI scans
Subscribe To Our Newsletter & Stay Updated